Xanax, Valium & Ativan: What Benzodiazepines Actually Do to Dementia Risk

This is one of the most searched — and most contested — medication questions in dementia care. Here's what the research honestly shows, including where it disagrees with itself.

What are benzodiazepines, and why are they so common in older adults?

Benzodiazepines calm the nervous system by boosting the effect of GABA, the brain's primary inhibitory chemical — which is why they work quickly for anxiety, panic, and sleep, and why they carry real sedation risk.

Common benzodiazepines include alprazolam (Xanax), diazepam (Valium), lorazepam (Ativan), and clonazepam (Klonopin). They're prescribed for anxiety, panic disorder, insomnia, seizures, and sometimes for agitation in dementia itself, since they act quickly and reliably calm an anxious or agitated person. That same calming action, though, comes from broadly suppressing central nervous system activity — which is also what makes them sedating, and why older adults are more sensitive to their effects than younger patients.

Do benzodiazepines cause dementia? The honest answer is: it's disputed.

Some studies found a link, others didn't, and the most recent large studies tend to find no increased risk — which is worth stating plainly rather than picking the study that fits a headline.

Early observational studies, particularly from the 2010s, reported associations between benzodiazepine use and increased dementia risk, with effect sizes in various meta-analyses ranging widely (roughly 1.4 to 1.8 times higher risk in some pooled estimates). But a review of five meta-analyses covering 30 studies found the underlying evidence was rated weak, with low methodological quality in many of the included studies — a signal that the association may be driven by factors other than the drug itself (for example, anxiety and insomnia are themselves early symptoms of developing dementia, which can make it look like the drug caused what it was actually treating).

More recent, larger studies have pushed back on the dementia-risk link specifically. A 2022 USC-led study following the question closely found benzodiazepine use did not increase dementia risk in older adults, though it did find evidence of accelerated brain-volume loss on imaging — a finding that doesn't necessarily translate to a dementia diagnosis but is worth taking seriously on its own.

The fair summary: unlike anticholinergic drugs, where the dose-response evidence for dementia risk is fairly consistent, the benzodiazepine-dementia link is genuinely unsettled science. Caregivers deserve to hear that uncertainty rather than a false sense of certainty in either direction.

What is well established, regardless of the dementia question

Even without a settled answer on dementia risk, benzodiazepines carry real, well-documented safety concerns for older adults that stand on their own.

• Falls and fractures — sedation and impaired coordination meaningfully raise fall risk in older adults, independent of any dementia link.
• Next-day grogginess and confusion, which can look like — or worsen — dementia symptoms without actually reflecting disease progression.
• The Beers Criteria, a widely used geriatric prescribing guideline, generally recommends avoiding benzodiazepines in older adults for exactly these reasons.
• Dependence and withdrawal — benzodiazepines are not meant for indefinite daily use, and stopping them abruptly after long-term use can be dangerous, including risk of seizures.

What caregivers should actually do

Treat the fall and confusion risk as the primary concern to raise with a doctor, whether or not the dementia-risk science ever fully resolves.

• If a loved one takes a benzodiazepine regularly, ask the doctor whether it's still the right long-term choice given fall and sedation risk, not just the dementia question.
• Never stop a benzodiazepine abruptly after regular use — a slow, medically supervised taper is essential to avoid withdrawal, which can include seizures in rare cases.
• If a benzodiazepine is being used for dementia-related agitation, ask about non-drug approaches first (routine, redirection, addressing unmet needs) and whether the dose or duration is being periodically reviewed.
• Watch for increased confusion or unsteadiness after a dose is started or increased, and report it — this may be the medication, not the underlying disease.